Robotic surgery is a market of giants, but the tools that fit on the end of their arms are a different story. Nami Surgical, a 2021 spin-out from the University of Glasgow, is building a business not on the robot itself, but on the miniature ultrasonic scalpels that do the cutting. The company’s recent £2.5 million seed round, plus a £700,000 Innovate UK grant, suggests its bet on component-level precision has found its first believers [Nami Surgical, June 2024].
The Component Wedge
Nami’s strategy is pragmatic. Instead of challenging Intuitive Surgical or Medtronic for control of the multi-million dollar console, the company is focusing on the instrument that interfaces directly with tissue. Its core product is a miniaturized ultrasonic surgical device designed for the tight confines of minimally invasive and robotic-assisted procedures [Nami Surgical, retrieved 2026]. The pitch is about performance: a tool that offers high precision and maneuverability for complex surgical tasks, potentially improving outcomes in areas like neurosurgery or delicate oncological work. For a hospital procurement office, this translates to a potential upgrade path for existing robotic systems, a less capital-intensive purchase than a new platform.
Funding the Clinical Path
The £3.2 million total raised in mid-2024 was led by Eos Advisory and included the Investment Fund for Scotland, British Business Bank, Scottish Enterprise, and SIS Ventures [Nami Surgical, June 2024]. This was followed by an additional reported £1.9 million in early 2026 from Eos, Scottish Enterprise, and Maven Capital Partners [Preqin, February 2026]. The capital appears earmarked for advancing from prototype to clinical readiness. A key signal of this transition was the January 2026 appointment of Nikki Palfrey as CEO. Palfrey brings over 25 years of MedTech leadership experience, a move that suggests the board is prioritizing commercial scale and regulatory navigation over pure R&D [rutlandherald.com, retrieved 2026]. The company has also secured grant funding from Innovate UK, indicating its technology aligns with public-sector innovation goals.
June 2024 Seed Round | 2.5 | M GBP
June 2024 Innovate UK Grant | 0.7 | M GBP
February 2026 Venture Round | 1.9 | M GBP
The Realistic Competitive Set
Nami’s ideal customer is a medical device group or large hospital system running pilot programs for next-generation robotic surgery. The company says it has such pilots running worldwide, including in the United States [Social Investment Scotland, retrieved 2026]. For these buyers, the competitive evaluation is straightforward. They are not comparing Nami to Intuitive Surgical’s da Vinci system. They are evaluating its ultrasonic scalpel against the proprietary instruments offered by the robotic platform OEMs themselves, and against other specialized toolmakers like those within Stryker or Johnson & Johnson. Nami’s path depends on proving its tool offers a tangible clinical advantage,better cutting, less thermal damage, access to new anatomies,that justifies the complexity of integrating a third-party component into a tightly controlled surgical workflow.
Where the Scalpel Meets the System
The primary risk for Nami is not technical feasibility, but systems integration and the sales cycle. Robotic surgery platforms are closed ecosystems by design, favoring proprietary instruments that guarantee performance and simplify regulatory clearance. Convincing a hospital to adopt a new tool requires navigating not just clinical trials and FDA or CE marking, but also securing integration partnerships with the platform makers themselves. Furthermore, the company’s stated aim to transform the $9 billion robotic-assisted surgery market is a vision, not a current metric; the more immediate market is the segment for advanced surgical instruments within that larger space [Nami Surgical, retrieved 2026]. The recent CEO change is a direct address to these commercial hurdles, but the renewal motion,convincing a hospital to re-order these specialized, likely high-cost disposable instruments year after year,remains unproven.
The company’s progress will be measured by named clinical partnerships and a clear regulatory timeline. With a seasoned commercial leader now at the helm and multiple funding rounds closed, Nami Surgical has assembled the resources to test its wedge. The next twelve months should reveal whether its miniature ultrasonic scalpel can cut through the entrenched supply chains of robotic surgery.
Sources
- [Nami Surgical, June 2024] Nami Surgical secures £3.2 million in seed funding and grant | https://www.namisurgical.com/2024/06/
- [Nami Surgical, retrieved 2026] Company homepage and product description | https://www.namisurgical.com/
- [Preqin, February 2026] Nami Surgical raises GBP 1.9 million | https://www.preqin.com/
- [rutlandherald.com, retrieved 2026] Ultrasonic Surgery Specialist Nami Appoints Nikki Palfrey as CEO | https://www.rutlandherald.com/news/business/ultrasonic-surgery-specialist-nami-appoints-nikki-palfrey-as-ceo-and-completes-latest-investment-round/article_2f9bd021-50e8-5d0b-98d7-426eeaccb1b7.html
- [Social Investment Scotland, retrieved 2026] Nami Surgical company profile | https://www.socialinvestmentscotland.com/